Health Care

Takeda’s oral TYK2 inhibitor zasocitinib outperforms FDA‑approved deucravacitinib in early and durable psoriasis clearance, with a safe profile and expansion into arthritis, IBD, vitiligo and hidradenitis suppurativa.

Smith & Ne phew plc redeems its 5.150 % notes due 2027 on Oct 5, 2026, paying principal plus a modest premium to note holders—boosting debt ratios and future EBIT.

Genmab’s share rise signals investor confidence in talquetamab, a bispecific antibody with 77% response and manageable safety, hinting at a new multiple‑myeloma option soon.

Explore Philips’ AI‑enabled ultrasound platform: how it boosts imaging throughput, cuts costs, and drives market growth for medical imaging tech investors.

Explore AstraZeneca’s $2 billion partnership with Summit Therapeutics, unveiling dual‑targeted oncology drugs, promising GI cancer outcomes and a clear regulatory roadmap.

Regeneron and Sanofi’s $8 billion alliance launches long‑acting antibodies for type‑2 inflammation, aiming to boost adherence and capture a larger immune‑disease market.

Discover Eli Lilly’s breakthrough clinical results: EloraTZP’s 9.5 kg weight loss, Foundayo’s cardio‑safety, and EBGLYSS’s rapid atopic dermatitis relief.

Analyst reviews boost Sartorius Stedim Biotech, showing the stock under‑priced amid strong CMS growth, ESG‑aligned tech, and near‑term upside.

Royalty Pharma’s latest SEC filings reveal insider equity conversions—Bonnie Bassler’s 80k share boost and EVP Urist Marshall’s 4,100‑share purchase—showing how equity incentives align executives with shareholders.

Centene insider stock buys reveal execs’ commitment to value‑based care, tech investment and stronger shareholder alignment. Gain insights on how this shapes future strategy.